Compare KSCP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | PRLD |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 69.1M |
| IPO Year | 2022 | 2020 |
| Metric | KSCP | PRLD |
|---|---|---|
| Price | $3.98 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.67 | $4.00 |
| AVG Volume (30 Days) | ★ 536.1K | 428.1K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,610,000.00 | $10,500,000.00 |
| Revenue This Year | $9.63 | N/A |
| Revenue Next Year | $31.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.50 | ★ 250.00 |
| 52 Week Low | $2.45 | $0.61 |
| 52 Week High | $17.79 | $4.22 |
| Indicator | KSCP | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 68.38 |
| Support Level | $3.61 | $1.90 |
| Resistance Level | $5.41 | $2.38 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 23.14 | 96.12 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.